World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
34551
World Ranking
11218
National Ranking
5760

Research.com Recognitions

  • 2011 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Dihua Yu is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with significant focus on subfields including Molecular Biology, Immunology, Oncology, Pulmonary and Respiratory Medicine, and Cancer Research.

Their work covers a range of main topics related to cancer and immune function, including:

  • Immune Cell Function and Interaction
  • RNA modifications and cancer
  • Immune cells in cancer
  • Cancer-related molecular mechanisms research
  • Brain Metastases and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses

Dihua Yu has contributed extensively to scientific literature, with frequent publications in venues such as Cancer Research, Nature Communications, and the Journal of Clinical Investigation. Their publication record includes papers in journals like bioRxiv (Cold Spring Harbor Laboratory) and SSRN Electronic Journal as well.

Some recent papers published by or involving Dihua Yu include:

  • "Tumor microenvironment as a therapeutic target in cancer" (2020), published in Pharmacology & Therapeutics
  • "Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy" (2021), published in Nature Communications
  • "TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis" (2021), published in Journal of Clinical Investigation
  • "The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1" (2021), published in Cancer Cell
  • "Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells" (2021), published in Journal of Clinical Investigation

Frequent co-authors who have collaborated with Dihua Yu include:

  • Mien-Chie Hung
  • Jun Yao
  • Xiangliang Yuan
  • Yongkun Wei
  • Yimin Duan

Dihua Yu has been recognized as a Fellow of the American Association for the Advancement of Science (AAAS) since 2011.

Best Publications

  • PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

    Yoichi Nagata;Keng Hsueh Lan;Xiaoyan Zhou;Ming Tan

  • Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

    Rita Nahta;Dihua Yu;Mien Chie Hung;Gabriel N. Hortobagyi

  • Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth

    Lin Zhang;Siyuan Zhang;Siyuan Zhang;Jun Yao;Frank J. Lowery

  • Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

    Chia Wei Li;Seung Oe Lim;Weiya Xia;Heng Huan Lee

  • p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs

    Chun Ju Chang;Chi Hong Chao;Weiya Xia;Jer Yen Yang;Jer Yen Yang

  • ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation

    Jer Yen Yang;Cong S. Zong;Weiya Xia;Hirohito Yamaguchi

  • Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis

    Yan M. Li;Yong Pan;Yongkun Wei;Xiaoyun Cheng;Xiaoyun Cheng

  • Deubiquitination and Stabilization of PD-L1 by CSN5

    Seung Oe Lim;Chia Wei Li;Weiya Xia;Jong Ho Cha

  • Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

    Siyuan Zhang;Wen Chien Huang;Ping Li;Hua Guo

  • Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.

    Dihua Yu;Mien Chie Hung

  • Overexpression of ErbB2 Blocks Taxol-Induced Apoptosis by Upregulation of p21Cip1, which Inhibits p34Cdc2 Kinase

    Dihua Yu;Tong Jing;Bolin Liu;Jun Yao

  • Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers

    Xiaoyan Zhou;Ming Tan;Valerie Stone Hawthorne;Kristine S. Klos

  • The Skp2-SCF E3 ligase regulates akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis

    Chia Hsin Chan;Chien Feng Li;Chien Feng Li;Wei Lei Yang;Wei Lei Yang;Yuan Gao;Yuan Gao

  • Enhanced c-erbB-2/neu Expression in Human Ovarian Cancer Cells Correlates With More Severe Malignancy That Can Be Suppressed by E1A

    Dihua Yu;Judith K. Wolf;Michael Scanlon;Janet E. Price

  • Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy.

    Riyao Yang;Linlin Sun;Linlin Sun;Ching Fei Li;Yu Han Wang;Yu Han Wang

  • PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

    Francisco J. Esteva;Hua Guo;Hua Guo;Siyuan Zhang;Cesar Santa-Maria

  • A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.

    Jeremy D. Henson;Jonathan A. Hannay;Stanley W. McCarthy;Janice A. Royds;Janice A. Royds

  • Targeting Src family kinases in anti-cancer therapies: turning promise into triumph

    Siyuan Zhang;Dihua Yu

  • Erratum: P53 regulates epithelial, mesenchymal transition and stem cell properties through modulating miRNAs (Nature Cell Biology (2011) 13 (317-323))

    Chun Ju Chang;Chi Hong Chao;Weiya Xia;Jer Yen Yang

  • PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients.

    Keng-Hsueh Lan;Yoichi Nagata;Xiaoyan Zhou;Francisco J. Esteva

Frequent Co-Authors

Mien Chie Hung
Mien Chie Hung China Medical University
Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Raphael E. Pollock
Raphael E. Pollock The Ohio State University
Weiya Xia
Weiya Xia The University of Texas MD Anderson Cancer Center
Jun Yao
Jun Yao The University of Texas MD Anderson Cancer Center
Aysegul A. Sahin
Aysegul A. Sahin The University of Texas MD Anderson Cancer Center
Francisco J. Esteva
Francisco J. Esteva New York University
Yongkun Wei
Yongkun Wei The University of Texas MD Anderson Cancer Center
Gordon B. Mills
Gordon B. Mills Oregon Health & Science University
Patricia S. Steeg
Patricia S. Steeg National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Aspiring medical professionals in the USA increasingly rely on flexible, accredited online programs to advance their education and career opportunities. For those interested in healthcare leadership, exploring the top cahme-accredited mha programs can help you step into managerial and administrative roles in hospitals or health systems.

Nursing professionals can find pathways like the rn to bsn online no clinicals accredited programs, which offer a convenient way for registered nurses to earn their bachelor's degree without additional clinical requirements.

For those targeting advanced practice, the dnp online programs offer fast-track options to gain Doctor of Nursing Practice credentials. Some students might prefer an even more flexible route such as the dnp program without clinical hours, suitable for those with substantial experience looking to further their expertise.

Choosing the right online program can open diverse career pathways in medicine and beyond, supporting your growth in an ever-evolving healthcare landscape.

Best Scientists Citing Dihua Yu

Trending Scientists

Recently Published Articles